Abstract 2156
Background
The mobile application is a valuable tool in the transmission of information in terms of having easy access in our daily lives and hosting applications containing information specific to many diseases. After breast cancer surgery, the patients are generally preferred to have verbal expressions in their education. In this context, it is considered that mobile application is the right choice in order to provide the opportunity for the patients to manage their post-operative processes, to facilitate their access to the right information and to provide a positive contribution to their quality of life by providing consultancy services.
Methods
The text content of the mobile application has text, image, video and audio equipment as well as online support / consulting services. It is thought that the mobile application will have a separate interface for each problem, and text and animation content will be the only problem for each interface. Care was taken to ensure that the created interfaces were of different colors and the layout to be used for problem solving was similar for each interface. It was ensured that the patients were checked from the admin panel if they did not watch or watch the videos again. All these operations were entered by entering the user name and password and recorded by end-to-end encryption.
Results
Supporting self-care for a woman who has not yet achieved her responsibility to cope with all responsibilities will contribute to the maintenance of family unity. In the creation of a mobile application that can be reached continuously; It is aimed to support self-care, create a tool that can receive support without any social isolation, decrease individual dependence and increase self-esteem. Thus, the fact that the woman does not have to spend the post-operative period at home and can be used individually and at the desired time constitutes the other advantages of the mobile application.
Conclusions
If the patient with breast surgery has an equipment to support self-care in the post-operative home, it will be possible to decrease the rate of experiencing physiological, psychological and sociological problems. It will be possible for the patient who has no problems to decrease their applications to the hospital and to contribute to the economy of the country.
Clinical trial identification
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract